Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07171606RecruitingPhase 2
Study of a new drug for advanced lung cancer
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
ShanghaiAges 18–75 - NCT07170995RecruitingPhase 3
Study of SHR-8068 with adebrelimab and chemo for lung cancer
This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.
Jinan, ShandongAges 18–75 - NCT07169994RecruitingPhase 1/Phase 2
Testing YL202 with other cancer treatments for advanced solid tumors
This trial is testing a new drug called YL202 in combination with other anti-cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if this combination can shrink tumors or slow their growth.
Hefei, AnhuiAges 18–75 - NCT07166601RecruitingPhase 1
Study of a drug for advanced solid tumors with MUC-1 marker
This trial tests a new drug, M0324, alone or combined with pembrolizumab or chemotherapy, for advanced solid tumors that have a protein called MUC-1 on their surface. It may be an option for patients whose cancer has not responded to standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT07164885Recruiting
RAPART trial for advanced lung cancer patients
This trial tests a treatment for stage 3 lung cancer that cannot be removed with surgery. It includes people who have had other treatments before, like chemo or immunotherapy.
Shenzhen, GuangdongAges 18 years+ - NCT07173868Recruiting
PET scans for advanced breast cancer treatment planning
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
Seoul, Gannam-guAges 19 years+ - NCT07172256RecruitingPhase 2
CUE-101 plus pembrolizumab for HPV+ throat cancer
This trial tests a new drug called CUE-101 combined with a standard immunotherapy (pembrolizumab) for people with HPV-16 positive head and neck cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT06497010RecruitingEarly Phase 1
Personalized mRNA cancer vaccine for advanced solid tumors
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
Guiyang, China/GuizhouAges 18–75 - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT07158489RecruitingPhase 2
New drug combo for advanced lung cancer after immunotherapy
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
BadenAges 18 years+ - NCT07158528Recruiting
Gum grafting study for multiple receding gums in upper jaw
This study compares two gum grafting techniques (CAF and TCAF) to see which one works better for treating multiple receding gums in the upper jaw. It may help if you have gum recession and want a treatment to cover the exposed roots.
Ghent, Oost-VlaanderenAges 18 years+ - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07163325RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new oral drug called EP102 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and works by targeting a protein called METTL3.
BrusselsAges 18 years+ - NCT07161414RecruitingPhase 1
Study of rilvegostomig for advanced solid tumors
This study tests a new investigational drug, rilvegostomig, given as an injection under the skin. It is for people with advanced solid tumors that have not responded to or have progressed after standard treatments. The goal is to see how the drug behaves in the body and to assess its safety.
Huntersville, North CarolinaAges 18 years+ - NCT05263960RecruitingPhase 1/Phase 2
CM350 drug study for advanced solid tumors
This trial tests CM350 in people with advanced solid cancers that are hard to treat with standard options. It may help by finding a safe dose and whether the drug can work against these cancers.
Chengdu, SichuanAges 18–75 - NCT06956716RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for advanced bile duct cancer
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07147348RecruitingPhase 1/Phase 2
BNT3212 alone or with BNT327 for advanced solid tumors
This trial tests a new drug called BNT3212, either alone or combined with BNT327, in people with advanced solid tumors that have not gotten better with standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth.
AdelaideAges 18 years+ - NCT07147101Recruiting
Immunotherapy for advanced liver cancer: a study on effectiveness and immune response
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07150949RecruitingPhase 2
Comparing two radiation schedules with chemotherapy and immunotherapy for rectal cancer
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06304571RecruitingPhase 1
Study of HC006 for advanced solid tumors
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05190094RecruitingPhase 2
Test blood-based laser scan to guide first-line breast cancer treatment
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
BlidaAges 18 years+ - NCT07143045Recruiting
Zorifertinib for lung cancer that has spread to the brain
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
Hefei, AnhuiAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.